NASDAQ: LNAILunai Bioworks Inc Stock
$1.03-0.03 (-2.83%)
Updated Nov 17, 2025
LNAI Price
$1.03
Fair Value Price
-$1.03
Market Cap
$24.14M
52 Week Low
$0.12
52 Week High
$2.10
P/E
-0.13x
P/B
-1.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$130.98M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.53
Operating Cash Flow
-$7M
Beta
1.37
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LNAI Overview
A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LNAI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LNAI
Ranked#242 of 480
Ranked#242 of 480
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.10 | A | |
| $104.17 | A | |
| $170.09 | A |
Be the first to know about important LNAI news, forecast changes, insider trades & much more!
LNAI News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LNAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LNAI ($1.03) is overvalued by 199.63% relative to our estimate of its Fair Value price of -$1.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LNAI ($1.03) is not significantly undervalued (199.63%) relative to our estimate of its Fair Value price of -$1.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LNAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LNAI due diligence checks available for Premium users.
Valuation
LNAI fair value
Fair Value of LNAI stock based on Discounted Cash Flow (DCF)
Price
$1.03
Fair Value
-$1.03
Undervalued by
199.63%
LNAI ($1.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LNAI ($1.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LNAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LNAI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.13x
Industry
297.36x
Market
45.02x
LNAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.85x
Industry
5.14x
LNAI's financial health
Profit margin
Revenue
$0.0
Net Income
$2.8M
Profit Margin
0%
LNAI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.0M
Liabilities
$20.0M
Debt to equity
-1.53
LNAI's short-term liabilities ($19.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LNAI's short-term assets ($800.36k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LNAI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LNAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.3M
Investing
$544.7k
Financing
$1.3M
LNAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LNAI vs Biotech Stocks
Lunai Bioworks Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.